Kura Oncology's Upcoming Engagement with Investors
Kura Oncology, Inc. (NASDAQ: KURA) is making strides in the biopharmaceutical sector, focusing on precision medicine to combat cancer. The management team has announced an exciting opportunity for investors as they prepare to participate in a key investor conference.
Event Details of the Investor Conference
Kura will be featured at the UBS Virtual Oncology Day, scheduled for a strategic time slot that maximizes engagement: Wednesday, October 1, 2025, at 2:30 p.m. ET / 11:30 a.m. PT. This event represents a vital platform for Kura to connect with current and potential investors, presenting critical insights into their groundbreaking research and development efforts.
How to Access the Live Webcast
Investors interested in following Kura's presentations can do so through a live audio webcast accessible via the Investors section of Kura's official website. An archived replay will also be made available for those unable to attend live.
Understanding Kura Oncology's Mission
At the heart of Kura Oncology's mission is the commitment to developing cutting-edge therapies that hold the potential to change the way cancer is treated. As a clinical-stage biopharmaceutical company, Kura focuses on formulating small molecule drug candidates, specifically designed to target cancer signaling pathways. This approach aims to address high-need hematologic malignancies and solid tumors effectively.
Innovative Therapies in Development
Kura's pipeline includes ziftomenib, a menin inhibitor that targets specific genetic mutations seen in acute myeloid leukemia. By innovating within the realms of menin inhibition and farnesyl transferase inhibition, Kura Oncology is dedicated to overcoming the challenges posed by adaptive and innate resistance encountered when treating solid tumors.
The Importance of Investor Communication
Engaging with investors is not merely a formality; it is fundamental to Kura's progress as an organization. By providing updates on their pipeline and research initiatives, Kura emphasizes transparency and builds trust with stakeholders who are investing in the future of cancer therapy.
Continued Growth Through Investor Interaction
Investor conferences open doors to essential discussions about advancements in medical science, financial prospects, and community alignment. Kura Oncology recognizes the significance of these interactions, ensuring continuous growth and improvement through investor feedback and engagement.
Company Contacts for Further Information
For those who wish to learn more about Kura Oncology, the company encourages inquiries from investors and media alike. Greg Mann, who handles investor and media relations can be reached at 858-987-4046 or via email.
Frequently Asked Questions
1. What is the main focus of Kura Oncology?
Kura Oncology is primarily dedicated to developing precision medicines for cancer treatment.
2. Where can I find information about the investor conference?
Details about the conference can be found on Kura's official website under the Investors section.
3. What is ziftomenib?
Ziftomenib is a drug candidate being developed by Kura that targets genetic drivers of acute myeloid leukaemias.
4. Why is investor engagement important for Kura?
Investor engagement helps Kura maintain transparency and build trust while gaining insights for growth.
5. Who can I contact for more information about Kura Oncology?
For inquiries, you can contact Greg Mann from Kura's investor relations team.
